Terms: = Lymphoma AND BCL2, Bcl-2, 596, ENSG00000171791 AND Clinical Outcome
178 results:
1. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
[TBL] [Abstract] [Full Text] [Related]
2. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
3. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
[TBL] [Abstract] [Full Text] [Related]
4. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell lymphoma, Not Otherwise Specified.
Qiu L; Lin P; Khanlari M; Xu J; Cohen EN; Garces S; Miranda RN; Wang W; Fang H; Bueso-Ramos CE; Medeiros LJ; Li S
Mod Pathol; 2023 Dec; 36(12):100349. PubMed ID: 37820764
[TBL] [Abstract] [Full Text] [Related]
5. bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological Characterization of Primary Diffuse Large B-Cell lymphoma of the Central Nervous System.
Woo HY; Chae SW; DO SI; Na K
Anticancer Res; 2022 Nov; 42(11):5601-5608. PubMed ID: 36288864
[TBL] [Abstract] [Full Text] [Related]
7. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell lymphoma.
Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
[TBL] [Abstract] [Full Text] [Related]
8. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
9. Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies.
Zander T; Xue J; Markson G; Dahm F; Renner C
Anticancer Res; 2022 Apr; 42(4):1821-1832. PubMed ID: 35347000
[TBL] [Abstract] [Full Text] [Related]
10. AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and bcl2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Itou A; Ikoma H; Tomita S; Shiraiwa S; Ando K; Nakamura N
Pathol Int; 2022 Jan; 72(1):35-42. PubMed ID: 34727403
[TBL] [Abstract] [Full Text] [Related]
11. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and bcl2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
12. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
[TBL] [Abstract] [Full Text] [Related]
13. CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
[TBL] [Abstract] [Full Text] [Related]
14. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract] [Full Text] [Related]
15. Frequency Of Double Expressor lymphoma In A Tertiary Care Hospital.
Hassan M; Khattak MT; Qamar MA; Javed S; Saeed SU
J Ayub Med Coll Abbottabad; 2021; 33(1):44-48. PubMed ID: 33774953
[TBL] [Abstract] [Full Text] [Related]
16. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
[TBL] [Abstract] [Full Text] [Related]
17. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
[TBL] [Abstract] [Full Text] [Related]
18. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract] [Full Text] [Related]
19. Aggressive B-cell lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract] [Full Text] [Related]
20. LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217.
Ma HZ; Wang J; Shi J; Zhang W; Zhou DS
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):5933-5945. PubMed ID: 32572906
[TBL] [Abstract] [Full Text] [Related]
[Next]
